Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 966503

Cover Image

PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 966503

U.S. Acromegaly Drugs Market - Industry Trends and Forecast to 2027

PUBLISHED:
PAGES: 111 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Web Access (Single User License) - Read Only
USD 3500
Web Access (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

U.S. acromegaly drugs market is projected to register a CAGR of 6.4% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

U.S. Acromegaly Drugs Market, By Disease Type, (Pseudoacromegaly, Ectopic Acromegaly), Drug Class, (Somatostatin Analogues, Growth Hormone Receptor Antagonists, Dopamine Agonists), Drugs Type (Branded Generic), Route of Administration (Parenteral, Oral), End User (Hospitals, Specialty Clinics, Homecare, others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online pharmacy) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the U.S. acromegaly drugs market are:

Growing prevalence of acromegaly

Growing geriatric population

Market Players

The key market players for the U.S. acromegaly drugs market are listed below:

Novartis AG

Mylan N.V.

Ipsen Pharma

Pfizer Inc.

Fresenius Kabi USA (A Subsidiary of Fresenius Kabi AG)

Zydus Pharmaceuticals Inc. (A Subsidiary of Zydus Cadila)

Par Pharmaceuticals (A Subsidiary of Endo International plc)

Hikma Pharmaceuticals PLC

Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.)

Chiasma, Inc.

Ingenus Pharmaceuticals, LLC

Recordati Rare Diseases (A Subsidiary of RECORDATI S.p.A.)

Sun Pharmaceutical Industries Ltd.

Sagent Pharmaceuticals, Inc. (A Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.)

TABLE OF CONTENTS

1 INTRODUCTION 11

  • 1.1 OBJECTIVES OF THE STUDY 11
  • 1.2 MARKET DEFINITION 11
  • 1.3 OVERVIEW OF THE U.S. ACROMEGALY DRUGS MARKET 11
  • 1.4 CURRENCY AND PRICING 12
  • 1.5 LIMITATIONS 13
  • 1.6 MARKETS COVERED 13

2 MARKET SEGMENTATION 15

  • 2.1 MARKETS COVERED 15
  • 2.2 GEOGRAPHICAL SCOPE 16
  • 2.3 YEARS CONSIDERED FOR THE STUDY 16
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 17
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 20
  • 2.6 MULTIVARIATE MODELLING 21
  • 2.7 DISEASE TYPE LIFELINE CURVE 21
  • 2.8 DBMR MARKET POSITION GRID 22
  • 2.9 SECONDARY SOURCES 24
  • 2.10 ASSUMPTIONS 24

3 EXECUTIVE SUMMARY 25

4 PIPELINE ANALYSIS 28

5 EPIDEMIOLOGY 29

6 MARKET OVERVIEW 30

  • 6.1 DRIVERS 32
    • 6.1.1 GROWING PREVALENCE OF ACROMEGALY 32
    • 6.1.2 INCREASING PREVALENCE OF HORMONAL DISEASES, ENDOCRINE DISEASES AND HYPOPITUITARISM 32
    • 6.1.3 GROWING GERIATRIC POPULATION 33
    • 6.1.4 RISING AWARENESS ABOUT ACROMEGALY 33
    • 6.1.5 RISING R&D EXPENDITURE 34
  • 6.2 RESTRAINTS 34
    • 6.2.1 HIGH COST OF DRUGS 34
    • 6.2.2 LACK OF EARLY DETECTION 35
    • 6.2.3 COMPLICATIONS ASSOCIATED WITH TREATMENT 35
  • 6.3 OPPORTUNITIES 36
    • 6.3.1 GROWING NUMBER OF DENTAL CLINICS 36
    • 6.3.2 GROWING HEALTHCARE EXPENDITURE IN THE U.S. 36
    • 6.3.3 RISING PRODUCT APPROVAL 37
    • 6.3.4 RISING SEDENTARY LIFESTYLE ACROSS THE U.S. 37
  • 6.4 CHALLENGES 38
    • 6.4.1 STRINGENT REGULATION POLICIES 38
    • 6.4.2 PATENT EXPIRY OF DRUGS 40

7 COVID-19 IMPACT ON ACROMEGALY DRUGS MARKET IN HEALTHCARE INDUSTRY 41

  • 7.1 PRICE IMPACT 41
  • 7.2 IMPACT ON DEMAND 41
  • 7.3 IMPACT ON SUPPLY CHAIN 41
  • 7.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19 42
  • 7.5 CONCLUSION 42

8 U.S. ACROMEGALY DRUGS MARKET, BY DISEASE TYPE 44

  • 8.1 OVERVIEW 45
  • 8.2 ECTOPIC ACROMEGALY 48
  • 8.3 PSEUDOACROMEGALY 48

9 U.S. ACROMEGALY DRUGS MARKET, BY DRUGS CLASS 49

  • 9.1 OVERVIEW 50
  • 9.2 SOMATOSTATIN ANALOGUES 53
    • 9.2.1 OCTREOTIDE 53
    • 9.2.2 LANREOTIDE 53
    • 9.2.3 PASIREOTIDE 53
  • 9.3 GROWTH HORMONE RECEPTOR ANTAGONISTS 53
  • 9.4 DOPAMINE AGONISTS 54
    • 9.4.1 BROMOCRIPTINE 54
    • 9.4.2 CABERGOLINE 54

10 U.S. ACROMEGALY DRUGS MARKET, BY DRUGS TYPE 55

  • 10.1 OVERVIEW 56
  • 10.2 BRANDED 59
    • 10.2.1 SOMATULINE DEPOT 59
    • 10.2.2 SOMAVERT 59
    • 10.2.3 SIGNIFOR 59
    • 10.2.4 OTHERS 59
  • 10.3 GENERIC 60

11 U.S. ACROMEGALY DRUGS MARKET, BY ROUTE OF ADMINISTRATION 61

  • 11.1 OVERVIEW 62
  • 11.2 PARENTERAL 65
    • 11.2.1 SUBCUTANEOUS 65
    • 11.2.2 INTRAMUSCULAR 65
    • 11.2.3 INTRAVENOUS 65
  • 11.3 ORAL 65

12 U.S. ACROMEGALY DRUGS MARKET, BY END USER 67

  • 12.1 OVERVIEW 68
  • 12.2 HOSPITALS 71
  • 12.3 SPECIALTY CLINICS 71
  • 12.4 HOMECARE 71
  • 12.5 OTHERS 72

13 U.S. ACROMEGALY DRUGS MARKET, BY DISTRIBUTION CHANNEL 73

  • 13.1 OVERVIEW 74
  • 13.2 HOSPITALS PHARMACY 77
  • 13.3 RETAIL PHARMACY 77
  • 13.4 ONLINE PHARMACY 77

14 U.S. ACROMEGALY DRUGS MARKET: COMPANY LANDSCAPE 79

  • 14.1 COMPANY SHARE ANALYSIS: U.S. 79

15 SWOT ANALYSIS 80

16 COMPANY PROFILES 81

  • 16.1 IPSEN PHARMA 81
    • 16.1.1 COMPANY SNAPSHOT 81
    • 16.1.2 REVENUE ANALYSIS 81
    • 16.1.3 PRODUCT PORTFOLIO 82
    • 16.1.4 RECENT DEVELOPMENTS 82
  • 16.2 NOVARTIS AG 83
    • 16.2.1 COMPANY SNAPSHOT 83
    • 16.2.2 REVENUE ANALYSIS 83
    • 16.2.3 PRODUCT PORTFOLIO 83
    • 16.2.4 RECENT DEVELOPMENTS 84
  • 16.3 PFIZER INC. 85
    • 16.3.1 COMPANY SNAPSHOT 85
    • 16.3.2 REVENUE ANALYSIS 85
    • 16.3.3 PRODUCT PORTFOLIO 85
    • 16.3.4 RECENT DEVELOPMENTS 86
  • 16.4 RECORDATI RARE DISEASES (A SUBSIDIARY OF RECORDATI S.P.A.) 87
    • 16.4.1 COMPANY SNAPSHOT 87
    • 16.4.2 REVENUE ANALYSIS 87
    • 16.4.3 PRODUCT PORTFOLIO 88
    • 16.4.4 RECENT DEVELOPMENT 88
  • 16.5 CHIASMA, INC. 89
    • 16.5.1 COMPANY SNAPSHOT 89
    • 16.5.2 PRODUCT PORTFOLIO 89
    • 16.5.3 RECENT DEVELOPMENTS 89
  • 16.6 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS KABI AG) 91
    • 16.6.1 COMPANY SNAPSHOT 91
    • 16.6.2 REVENUE ANALYSIS 91
    • 16.6.3 PRODUCT PORTFOLIO 91
    • 16.6.4 RECENT DEVELOPMENTS 92
  • 16.7 HIKMA PHARMACEUTICALS PLC 93
    • 16.7.1 COMPANY SNAPSHOT 93
    • 16.7.2 REVENUE ANALYSIS 93
    • 16.7.3 PRODUCT PORTFOLIO 94
    • 16.7.4 RECENT DEVELOPMENTS 94
  • 16.8 INGENUS PHARMACEUTICALS, LLC 95
    • 16.8.1 COMPANY SNAPSHOT 95
    • 16.8.2 PRODUCT PORTFOLIO 95
    • 16.8.3 RECENT DEVELOPMENT 95
  • 16.9 MYLAN N.V. 96
    • 16.9.1 COMPANY SNAPSHOT 96
    • 16.9.2 REVENUE ANALYSIS 96
    • 16.9.3 PRODUCT PORTFOLIO 96
    • 16.9.4 RECENT DEVELOPMENTS 97
  • 16.10 PAR PHARMACEUTICAL (A SUBSIDIARY OF ENDO INTERNATIONAL PLC) 98
    • 16.10.1 COMPANY SNAPSHOT 98
    • 16.10.2 REVENUE ANALYSIS 98
    • 16.10.3 PRODUCT PORTFOLIO 99
    • 16.10.4 RECENT DEVELOPMENTS 99
  • 16.11 SAGENT PHARMACEUTICALS, INC. (A SUBSIDIARY OF NICHI-IKO PHARMACEUTICAL CO., LTD.) 100
    • 16.11.1 COMPANY SNAPSHOT 100
    • 16.11.2 REVENUE ANALYSIS 100
    • 16.11.3 PRODUCT PORTFOLIO 101
    • 16.11.4 RECENT DEVELOPMENT 101
  • 16.12 SUN PHARMACEUTICAL INDUSTRIES LTD. 102
    • 16.12.1 COMPANY SNAPSHOT 102
    • 16.12.2 REVENUE ANALYSIS 102
    • 16.12.3 PRODUCT PORTFOLIO 102
    • 16.12.4 RECENT DEVELOPMENTS 103
  • 16.13 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY TEVA PHARMACEUTICAL INDUSTRIES LTD.) 104
    • 16.13.1 COMPANY SNAPSHOT 104
    • 16.13.2 REVENUE ANALYSIS 104
    • 16.13.3 PRODUCT PORTFOLIO 105
    • 16.13.4 RECENT DEVELOPMENTS 105
  • 16.14 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA) 106
    • 16.14.1 COMPANY SNAPSHOT 106
    • 16.14.2 REVENUE ANALYSIS 106
    • 16.14.3 PRODUCT PORTFOLIO 107
    • 16.14.4 RECENT DEVELOPMENTS 107

17 QUESTIONNAIRE 108

18 RELATED REPORTS 111

LIST OF TABLES

  • TABLE 1 U.S. ACROMEGALY DRUGS MARKET, PIPELINE ANALYSIS 28
  • TABLE 2 PRICES OF ACROMEGALY DRUGS IN USD 34
  • TABLE 3 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED 39
  • TABLE 4 U.S. ACROMEGALY DRUGS MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION) 47
  • TABLE 5 U.S. ACROMEGALY DRUGS MARKET, BY DRUGS CLASS, 2018-2027 (USD MILLION) 52
  • TABLE 6 U.S. ACROMEGALY DRUGS MARKET, BY DRUGS CLASS, 2018-2027 (USD MILLION) 53
  • TABLE 7 U.S. ACROMEGALY DRUGS MARKET, BY DRUGS CLASS, 2018-2027 (USD MILLION) 54
  • TABLE 8 U.S. ACROMEGALY DRUGS MARKET, BY DRUGS TYPE, 2018-2027 (USD MILLION) 58
  • TABLE 9 U.S. ACROMEGALY DRUGS MARKET, BY DRUGS TYPE, 2018-2027 (USD MILLION) 59
  • TABLE 10 U.S. ACROMEGALY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION) 64
  • TABLE 11 U.S. PARENTERAL IN ACROMEGALY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION) 65
  • TABLE 12 U.S. ACROMEGALY DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION) 70
  • TABLE 13 U.S. ACROMEGALY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 76

LIST OF FIGURES

  • FIGURE 1 THE U.S. ACROMEGALY DRUGS MARKET: SEGMENTATION 15
  • FIGURE 2 THE U.S. ACROMEGALY DRUGS MARKET: DATA TRIANGULATION 17
  • FIGURE 3 THE U.S. ACROMEGALY DRUGS MARKET: DROC ANALYSIS 18
  • FIGURE 4 THE U.S. ACROMEGALY DRUGS MARKET: COUNTRY VS REGIONAL ANALYSIS 19
  • FIGURE 5 THE U.S. ACROMEGALY DRUGS MARKET: COMPANY RESEARCH ANALYSIS 19
  • FIGURE 6 THE U.S. ACROMEGALY DRUGS MARKET: INTERVIEW DEMOGRAPHICS 20
  • FIGURE 7 THE U.S. ACROMEGALY DRUGS MARKET: DBMR MARKET POSITION GRID 22
  • FIGURE 8 THE U.S. ACROMEGALY DRUGS MARKET: SEGMENTATION 26
  • FIGURE 9 GROWING PREVALENCE OF ACROMEGALY AND INCREASING PREVALENCE OF HORMONAL DISEASES, ENDOCRINE DISEASES AND HYPOPITUITARISM ARE EXPECTED TO DRIVE THE U.S. ACROMEGALY DRUGS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 27
  • FIGURE 10 ECTOPIC ACROMEGALY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. ACROMEGALY DRUGS MARKET IN 2020 & 2027 27
  • FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF U.S. ACROMEGALY DRUGS MARKET 31
  • FIGURE 12 U.S. ACROMEGALY DRUGS MARKET: BY DISEASE TYPE, 2019 45
  • FIGURE 13 U.S. ACROMEGALY DRUGS MARKET: BY DISEASE TYPE, 2019-2027 (USD MILLION) 46
  • FIGURE 14 U.S. ACROMEGALY DRUGS MARKET: BY DISEASE TYPE, CAGR (2020-2027) 46
  • FIGURE 15 U.S. ACROMEGALY DRUGS MARKET: BY DISEASE TYPE, LIFELINE CURVE 47
  • FIGURE 16 U.S. ACROMEGALY DRUGS MARKET: BY DRUGS CLASS, 2019 50
  • FIGURE 17 U.S. ACROMEGALY DRUGS MARKET: BY DRUGS CLASS, 2019-2027 (USD MILLION) 51
  • FIGURE 18 U.S. ACROMEGALY DRUGS MARKET: BY DRUGS CLASS, CAGR (2020-2027) 51
  • FIGURE 19 U.S. ACROMEGALY DRUGS MARKET: BY DRUGS CLASS, LIFELINE CURVE 52
  • FIGURE 20 U.S. ACROMEGALY DRUGS MARKET: BY DRUGS TYPE, 2019 56
  • FIGURE 21 U.S. ACROMEGALY DRUGS MARKET: BY DRUGS TYPE, 2019-2027 (USD MILLION) 57
  • FIGURE 22 U.S. ACROMEGALY DRUGS MARKET: BY DRUGS TYPE, CAGR (2020-2027) 57
  • FIGURE 23 U.S. ACROMEGALY DRUGS MARKET: BY DRUGS TYPE, LIFELINE CURVE 58
  • FIGURE 24 U.S. ACROMEGALY DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2019 62
  • FIGURE 25 U.S. ACROMEGALY DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION) 63
  • FIGURE 26 U.S. ACROMEGALY DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027) 63
  • FIGURE 27 U.S. ACROMEGALY DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 64
  • FIGURE 28 U.S. ACROMEGALY DRUGS MARKET: BY END USER, 2019 68
  • FIGURE 29 U.S. ACROMEGALY DRUGS MARKET: BY END USER, 2019-2027 (USD MILLION) 69
  • FIGURE 30 U.S. ACROMEGALY DRUGS MARKET: BY END USER, CAGR (2020-2027) 69
  • FIGURE 31 U.S. ACROMEGALY DRUGS MARKET: BY END USER, LIFELINE CURVE 70
  • FIGURE 32 U.S. ACROMEGALY DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2019 74
  • FIGURE 33 U.S. ACROMEGALY DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION) 75
  • FIGURE 34 U.S. ACROMEGALY DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027) 75
  • FIGURE 35 U.S. ACROMEGALY DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 76
  • FIGURE 36 U.S. ACROMEGALY DRUGS MARKET: COMPANY SHARE 2019 (%) 79
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!